Floatz logo

FLUTICASONE

Triple-Negative Breast Carcinoma

University of WashingtonSmall moleculePhase 2Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
89/ 100

Competitive context

16 Active assets in the Triple-Negative Breast Carcinoma cohort.

Asset / SponsorPhaseRating
Veliparib
National Cancer Institute (NCI)
Phase 3BB
Enzalutamide
Nuvation Bio Inc.
Phase 2BB
Alpelisib
The Methodist Hospital Research Institute
Phase 3BB
Binimetinib
National Cancer Institute (NCI)
Phase 2BB
Inno-206
Roswell Park Cancer Institute
Phase 3BB

View all 39 →

Same molecule, other indications

FLUTICASONE is also rated in:

Unspecified Adult Solid Tumor, Protocol SpecificDormant
BBB
Indicative ·
73 / 100
View asset →
Recurrent Adult Acute Myeloid LeukemiaDormant
BBB
Indicative ·
73 / 100
View asset →
Chronic Phase Chronic Myelogenous LeukemiaDormant
BB
Indicative ·
71 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →